Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.23.1
Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - Level 3 significant unobservable inputs - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance $ 2,882,285 $ 2,329,044
Net Realized Gains (Losses) [1] (832) 1,153
Net Change in Unrealized Appreciation (Depreciation) [2] 25,766 (13,113)
Purchases [3] 364,052 300,778
Sales 312 6,185
Repayments [4] 209,666 97,672
Gross Transfers into Level 3 [5]   207
Gross Transfers out of Level 3 [5]   13,868
Ending Balance 3,061,293 2,500,344
Senior Secured    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 2,741,388 2,156,709
Net Realized Gains (Losses) [1]   (2,010)
Net Change in Unrealized Appreciation (Depreciation) [2] 16,023 (8,696)
Purchases [3] 362,781 292,683
Repayments [4] 209,666 97,672
Gross Transfers out of Level 3 [5]   3,504
Ending Balance 2,910,526 2,337,510
Escrow Receivables    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 875 561
Net Realized Gains (Losses) [1] 26 277
Net Change in Unrealized Appreciation (Depreciation) [2]   (0)
Purchases [3]   167
Sales 98 345
Ending Balance 803 660
Unsecured Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 54,056 52,890
Net Change in Unrealized Appreciation (Depreciation) [2] 3,746 (259)
Purchases [3] 323 1,201
Ending Balance 58,125 53,832
Preferred Note    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 41,488 69,439
Net Realized Gains (Losses) [1]   2,867
Net Change in Unrealized Appreciation (Depreciation) [2] (1,143) (6,513)
Purchases [3]   2,903
Sales   4,772
Gross Transfers out of Level 3 [5]   6,422
Ending Balance 40,345 57,502
Common Stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 25,059 21,968
Net Realized Gains (Losses) [1]   (0)
Net Change in Unrealized Appreciation (Depreciation) [2] 5,632 2,241
Purchases [3]   0
Sales 207 0
Gross Transfers into Level 3 [5]   207
Gross Transfers out of Level 3 [5]   3,942
Ending Balance 30,484 20,474
Warrant    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 19,419 27,477
Net Realized Gains (Losses) [1] (858) 19
Net Change in Unrealized Appreciation (Depreciation) [2] 1,508 114
Purchases [3] 948 3,824
Sales 7 1,068
Ending Balance $ 21,010 $ 30,366
[1] Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations.
[2] Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.
[3] Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.
[4] Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
[5] Transfers out of Level 3 during the three months ended March 31, 2022, related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the three months ended March 31, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares.